Document is current
Any future updates will be listed below
-
Authors
Bretz, Anne Catherine
Parnitzke, Ulrike
Kronthaler, Kerstin
Dreker, Tobias
Bartz, René
Hermann, Frank
Ammendola, Astrid
Wulff, Tanja
Hamm, Svetlana http://orcid.org/0000-0002-8593-0076
-
Funding
Funding for this research was provided by:
Eurostars (E9683: EMTherapy)
- License Information
-
More Information
Article History
Received: 16 July 2019
Accepted: 20 September 2019
First Online: 8 November 2019
Ethics approval and consent to participate
: Animal housing and experimental procedures were performed in accordance with French and European Regulations and NRC Guide for the Care and Use of Laboratory Animals and received ethical approval by the responsible authorities.The SENSITIZE clinical trial (NCT03278665) received independent ethics committee approval and is conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonization, Guidance on Good Clinical Practice, and all regulatory requirements regarding conduct of human clinical trials. Written informed consent was obtained from each patient prior to any trial procedure.
: Not applicable.
: ACB, UP, KK, TD, RB, FH, AA, TW, SH are employees of 4SC; TD, SH are stakeholders of 4SC. FH, RB, and SH are currently applying for patents covering combination of domatinostat with immunotherapies.
